Other substances

Anisomycin

An antibiotic.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
0
 Clinical trials

General information

Anisomycin is a prokaryotic bacterial ribosomal peptidyl transferase inhibitor isolated from Streptomyces genus bacteria. It has also potential antiparasitic, antineoplastic, or antiviral properties (ChEBI).

Anisomycin on DrugBank
Anisomycin on PubChem
Anisomycin on Wikipedia


Synonyms

Flagecidin

 

Structure image - Anisomycin

CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O

Supporting references

Link Tested on Impact factor Notes Publication date
Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19
Small molecule In vitro In silico 		in silico; Vero E6 cells; SARS-CoV-2 strain hCoV-19/Taiwan/NTU13/2020

Cell treatment results in transcriptional response with high degree of similarity to interferon beta treatment. Potently inhibits SARS-CoV-2 infection in vitro (IC50 = 31.4 nM) with selectivity index of 9.87.

 Dec/02/2020

AI-suggested references

Link Publication date
Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates
Nov/01/2021
Enhancement of the IFN-beta-induced host signature informs repurposed drugs for COVID-19.
Dec/02/2020
Repurposing old drugs as antiviral agents for coronaviruses
May/23/2020
Export (.csv)